长链非编码RNA H19可预测不良预后和淋巴结转移：一项人类癌症的荟萃分析
Long non-coding RNA H19 can predict a poor prognosis and lymph node metastasis: a meta-analysis in human cancer.
作者信息
Chen Tao, Yang Peng, He Zhen Y
机构信息
The Second Clinical Medical College of Nanjing Medical University, Nanjing, China -
出版信息
Minerva Med. 2016 Aug;107(4):251-8.
INTRODUCTION
A long non-coding RNA (lncRNA) H19 has been reported to be aberrantly regulated in a wide range of cancers. This meta-analysis was performed to explore the potential value of H19 as a biomarker for cancer prognosis.
EVIDENCE ACQUISTION
We searched the electronic databases PubMed and Web of Science (up to April 30, 2016) in attention to collect all relevant researches to identify the association of lncRNA H19 with overall survival (OS), disease free survival (DFS) and lymph node metastasis (LNM).
EVIDENCE SYNTHESIS
Our findings revealed that high levels of H19 expression could predict poor OS (pooled HR: 1.19, 95% CI: 1.08-1.32, P=0.001) and LNM (pooled OR: 1.810, 95% CI: 1.27-2.59, P=0.001) in multiple cancers.
CONCLUSIONS
This meta-analysis showed that overexpression of H19 might potentially serve as a reliable biomarker for poor prognosis in different types of cancers.
引言
据报道，长链非编码RNA（lncRNA）H19在多种癌症中存在异常调控。本荟萃分析旨在探讨H19作为癌症预后生物标志物的潜在价值。
证据获取
我们检索了电子数据库PubMed和Web of Science（截至2016年4月30日），以收集所有相关研究，确定lncRNA H19与总生存期（OS）、无病生存期（DFS）和淋巴结转移（LNM）之间的关联。
证据综合
我们的研究结果显示，在多种癌症中，高水平的H19表达可预测较差的OS（合并风险比：1.19，95%置信区间：1.08 - 1.32，P = 0.001）和LNM（合并比值比：1.810，95%置信区间：1.27 - 2.59，P = 0.001）。
结论
本荟萃分析表明，H19的过表达可能是不同类型癌症预后不良的可靠生物标志物。
Zotero 插件